TrialTrials2014

Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial.

Barbara Burtness et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.